GENB · Generate Biomedicines, Inc. · Documents
$15.95
+0.43 (+2.77%)
At close · Sep 10
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had concluded that there was substantial doubt about its ability to continue as a going concern. Upon closing of the IPO and receipt of the associated cash proceeds, the Company has alleviated the substantial doubt that previously existed, and based on the Company’s current capital resources, which consists of its cash, cash equivalents and marketable securities on hand at June 30, 2026, it expects to have sufficient cash to fund our current operating plan into the first half of 2028.”View the 10-Q filed Aug 6, 2026
Market Cap
$2.03B
Shares
128.35M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-08-26 | 2026-08-25 | |
| 8-K | 2026-08-06 | — | |
| 10-Q | 2026-08-06 | 2026-06-30 | |
| Investor Event Transcript | 2026-06-08 | 2026-06-30 | |
| 8-K | 2026-05-07 | — | |
| 10-Q | 2026-05-07 | 2026-03-31 | |
| 8-K | 2026-03-02 | 2026-02-26 |
Showing 1–7 of 7 filings